FDA approves BMS’ Opdivo for urothelial carcinoma
The US FDA has granted approval for BMS' Opdivo for the first-line treatment of adults with unresectable or metastatic urothelial carcinoma.
The US FDA has granted approval for BMS' Opdivo for the first-line treatment of adults with unresectable or metastatic urothelial carcinoma.
What's Your Reaction?
